|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nutritional value of high fiber co-products from the copra,palm kernel,and rice industries in diets fed to pigs显示文摘High fiber co-products from the copra and palm kernel industries are by-products of the production of coconut oil and palm kernel oil. The co-products include copra meal, copra expellers, palm kernel meal, and palm kernel expellers. All 4 ingredients are very high in fiber and the energy value is relatively low when fed to pigs. The protein concentration is between 14 and 22 % and the protein has a low biological value and a very high Arg:Lys ratio. Digestibility of most amino acids is less than in soybean meal but close to that in corn. However, the digestibility of Lys is sometimes low due to Maillard reactions that are initiated due to overheating during drying.Copra and palm kernel ingredients contain 0.5 to 0.6 % P. Most of the P in palm kernel meal and palm kernel expellers is bound to phytate, but in copra products less than one third of the P is bound to phytate. The digestibility of P is, therefore, greater in copra meal and copra expellers than in palm kernel ingredients. Inclusion of copra meal should be less than 15 % in diets fed to weanling pigs and less than 25 % in diets for growing-finishing pigs. Palm kernel meal may be included by 15 % in diets for weanling pigs and 25 % in diets for growing and finishing pigs.Rice bran contains the pericarp and aleurone layers of brown rice that is removed before polished rice is produced.Rice bran contains approximately 25 % neutral detergent fiber and 25 to 30 % starch. Rice bran has a greater concentration of P than most other plant ingredients, but 75 to 90 % of the P is bound in phytate. Inclusion of microbial phytase in the diets is, therefore, necessary if rice bran is used. Rice bran may contain 15 to 24 % fat, but it may also have been defatted in which case the fat concentration is less than 5 %. Concentrations of digestible energy(DE) and metabolizable energy(ME) are slightly less in full fat rice bran than in corn, but defatted rice bran contains less than 75 % of the DE and ME in corn. The concentration of crude protein is 15 to 18 % in rice bran and the protein has a high biological value and most amino acids are well digested by pigs. Inclusion of rice bran in diets fed to pigs has yielded variable results and based on current research it is recommended that inclusion levels are less than 25 to 30 % in diets for growing-finishing pigs, and less than 20 % in diets for weanling pigs.However, there is a need for additional research to determine the inclusion rates that may be used for both full fat and defatted rice bran. | Hans Henrik Stein Gloria Amparo Casas Jerubella Jerusalem Abelilla Yanhong Liu Rommel Casilda Sulabo | 2016 | Journal of Animal Science and Biotechnology2016，7，2： | 3 |
| 2 | 18F-FDG PET in children with lymphomas显示文摘 | Depas G De Barsy C Jerusalem G | 2005 | Eur J Nucl Med Mol Imaging2005，32，1： | 1 |
| 3 | Final overall surviv- al: fulvestrant 500rag vs 250rag in the randomized CONFIRM trial显示文摘 | Di Leo A Jerusalem G Petruzelka L | 2014 | J Nati Cancer Inst2014，106，1： | 1 |
| 4 | Whole-body positron emission tomography using 18F-fluorodeoxyglucose in the staging of Hodgkin's disease and non-Hodgkin's lymphoma 显示文摘 | Jerusalem G Paulus P Warland V | 1995 | Eur J Nucl Med1995，22，： | 1 |
| 5 | PET scan imaging in oncology显示文摘 | Jerusalem G Hustinx R Beguin Y | 2003 | Eur J Cancer2003，39，11： | 1 |
| 6 | Persistent tumor 18F-FDG u-ptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma显示文摘 | Jerusalem G Beguin Y Fassotte MF | 2000 | Haematologica2000，85，6： | 1 |
| 7 | Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL) 显示文摘 | Jerusalem G Beguin Y Najjar F | 2001 | Ann Oncol2001，12，6： | 1 |
| 8 | Positron emission tomography(PET) for staging low-grade non-Hodgkin's lymphomas (NHL) 显示文摘 | Najjar F Hustinx R Jerusalem G | 2001 | Cancer Biother Radiopharm2001，16，4： | 1 |
| 9 | Results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer显示文摘 | Di Leo A Jerusalem G Petruzelka L | 2010 | J Clin Oncol2010，28，30： | 1 |
| 10 | Phase Ⅲ,randomized,double-blind,placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant,advanced breast cancer (BOLERO-3)显示文摘 | O' Regan R Ozguroglu M Andre F Toi M Jerusalem G Wilks S Isaacs C Xu B Masuda N Arena FP Yardley D Yap YS Mukhopadhyay P Douma S El-Hashimy M Taran T Sahmoud T Lebwohl D Gianni L | | 0，，15： | 1 |
| 11 | Final overall survival: fulvestrant 500 mg versus 250 mg in the randomized CONFIRM trial 显示文摘 | Di Leo A Jerusalem G Petruzelka L | 2014 | J Natl Cancer Inst2014，106，1： | 1 |
| 12 | PET scan imaging in oncology显示文摘 | JERUSALEM G HUSTINX R BEGUIN Y | 2003 | Eur J Cancer2003，39，11： | 1 |
| 13 | Evaluation of therapy for lymphoma 显示文摘 | Jerusalem G Hustinx R Beguin Y | 2005 | Semin Nucl Med2005，35，3： | 1 |
| 14 | PhaseⅠtrialof oral mTOR inhibitor everolimus in combination with trastuzumab andvinorelbine in pre-treated patients with HER2-overexpressing metastat-ic breast cancer显示文摘 | Guy Jerusalem Angelica Fasolo Veronique Dieras | 2010 | Breast Cancer Research and Treatment2010，125，： | 1 |
| 15 | Evaluation of therapy for lymphoma显示文摘 | Jerusalem G Hustinx R Beguin Y | 2005 | Semin Nuel Med2005，35，3： | 1 |
| 16 | Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)显示文摘 | Jerusalem G Beguin Y Najjar F | 2001 | Ann Oncol2001，12，6： | 1 |
| 17 | Positron emission tomography in non-Hodgkin's lymphoma (NHL):relationship between tracer uptake and pathological findings,including preliminary experience in the staging of low-grade NHL显示文摘 | Jerusalem GH Beguin YP | 2002 | Clin Lymphoma2002，3，1： | 1 |
| 18 | Results of the CONFIRM phaseIII trial comparing fulvestrant 250 mg with fulvestrant 500 rng in postmenopausal women with estrogen receptor- positive advanced breast cancer显示文摘 | Di Leo A Jerusalem G Petruzelka L | 2010 | J Clin Oneol2010，28，30： | 1 |
| 19 | Results of the CONFIRM phase m trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer 显示文摘 | Di Leo A Jerusalem G Petruzelka L | 2010 | J Clin Oncol2010，28，30： | 1 |
| 20 | Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial显示文摘 | Di Leo A Jerusalem G Petruzelka L | 2014 | JNatl Cancer Inst2014，106，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员